Acquired Hemophilia Treatment Market Is Expected To Reach USD 2,474.7 Mn By 2023 - Credence Research

The latest market report published by Credence Research, Inc. “Global Acquired Hemophilia Treatment Market - Growth, Share, Opportunities, Competitive Analysis, and Forecast, 2016 - 2023,” the acquired hemophilia treatment market was valued at USD 1,923.4 Mn in 2015, and is expected to reach USD 2,474.7 Mn by 2023, expanding at a CAGR of 3.2% from 2016 to 2023.

Browse the full report Acquired Hemophilia Treatment Market - Growth, Future Prospects, Competitive Analysis, 2016 – 2023 at http://www.credenceresearch.com/report/acquired-hemophilia-treatment-market

Market Insights

According to National Organization of Rare Disorders (NORD), acquired hemophilia is a rare autoimmune disorder characterized by bleeding that occurs in patients with a personal and family history negative for hemorrhages. In acquired hemophilia, the body produces antibodies that attack clotting factors, most often factor VIII. Medical practitioners suggest that, acquired hemophilia can potentially cause life-threatening bleeding complications in severe cases and in around 50% of cases, there is an identifiable underlying clinical condition; in the other 50% no cause is known i.e. idiopathic. Treatment strategies that are applied against acquired hemophilia are based on two major objectives. The primary objective is effective control of bleeding manifestations during acute bleeding episodes. The secondary and ultimate therapeutic objective is to eliminate the inhibitor and cure the disease. Thus, the global acquired hemophilia treatment market on the basis of therapeutics has been segmented into two major categories such as traditional therapies and advanced therapies.

The acquired hemophilia treatment market is observed to be majorly dominated by few players operating in the market.  The market is dominated by players, depending on their major competencies. The key players in this market are Baxalta, Inc. (Shire), Novo Nordisk, Biogen, Pfizer, Inc., and F. Hoffman La Roche. 

Request for customization research report @ http://www.credenceresearch.com/request-for-customization/57894

Based on the type of therapeutics, the acquired hemophilia treatment market is segmented into:

• Traditional Therapies
  • Steroid Treatment
  • Cytotoxic Treatment
  • Immunomodulatory Treatment
• Advanced Therapies
  • Desmopressin
  • Recombinant Activated Factor VII/NovoSeven
  • Recombinant Activated Factor VIII/Obizur
  • Activated Prothrombin Complex Concentrate (aPCC)/ FEIBA

According to National Organization of Rare Disorders (NORD), acquired hemophilia is a rare autoimmune disorder characterized by bleeding that occurs in patients with a personal and family history negative for hemorrhages. In acquired hemophilia, the body produces antibodies that attack clotting factors, most often factor VIII. Treatment strategies that are applied against acquired hemophilia are based on two major objectives. The primary objective is effective control of bleeding manifestations during acute bleeding episodes. The secondary and ultimate therapeutic objective is to eliminate the inhibitor and cure the disease. The acquired hemophilia treatment market on the basis of therapeutics has been segmented into two major categories such as traditional therapies and advanced therapies. The traditional therapies are further sub-categorized into steroid treatment, cytotoxic treatment and immunomodulatory treatment. The advanced therapies is further segmented into Desmopressin, Recombinant Activated Factor VII/NovoSeven, Recombinant Activated Factor VIII/Obizur, and Activated Prothrombin Complex Concentrate (aPCC)/ FEIBA. The advanced therapies held the largest segment due to introduction of novel therapies for the treatment of acquired hemophilia. Activated Prothrombin Complex Concentrate (aPCC)/ FEIBA held the largest market in 2015, due to better patient compliance, a prospective study reported that 100% patients had excellent hemostasis with FEIBA administration. However, the market for traditional therapies is expected to grow at a stable rate during for forecast period due to patent expiration of advanced therapy drug and introduction of breakthrough drugs that are currently in the clinical study.

Download sample research report @ http://www.credenceresearch.com/sample-request/57894

For the purpose of this study, the global acquired hemophilia treatment market is categorized into:

• North America
• Europe
• Asia Pacific
• Latin America (LATAM)
• Middle East and Africa (MEA)

North America was observed as the largest market for acquired hemophilia treatment in the base year 2015. Constituted by regional markets of U.S. and Canada; North America is the clear leader in the global acquired hemophilia treatment market. North America dominated the market due to aging population, supportive government policies, high awareness associated with hemophilia and types in people, and developed healthcare infrastructure. In developed countries of U.S. and Canada, the network of hemophilia care centers is well set with domestic government support. The primary management option is evolved in developed countries with early treatment of bleeding episodes and quick home therapy. Asia Pacific was observed as the attractive market in acquired hemophilia treatment due to emerging healthcare infrastructure, high disposable income, transforming government policies specific to orphan diseases diagnosis and treatment, and rising public awareness associated with healthcare insurance and disease diagnosis.

Related Reports :

http://www.credenceresearch.com/report/non-alcoholic-concentrated-syrup-market

http://www.credenceresearch.com/report/specialty-milk-formula-market